Acrobiosystems Co

Acrobiosystems Co CapEx Growth

The Year-over-Year CapEx Growth of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 22.61 %. In the previous year, Year-over-Year CapEx Growth was 29.98 % — a change of -24.58% (lower).

CapEx Growth

22.61 %

YoY

-24.58%

Last updated:

Year-over-Year CapEx Growth of Acrobiosystems Co is 2025 22.61 % . Year-over-Year CapEx Growth of Acrobiosystems Co was 2024 29.98 % . It decreases by -24.58% lower compared to the previous year.

The Acrobiosystems Co CapEx Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx Growth
Date
CapEx Growth
Jan 1, 2019
12.79 CNY
Jan 1, 2020
48.42 CNY
Jan 1, 2021
311.58 CNY
Jan 1, 2022
361.09 CNY
Jan 1, 2023
-54.73 CNY
Jan 1, 2024
29.98 CNY
Jan 1, 2025
22.61 CNY
The Acrobiosystems Co CapEx Growth history
YEARCapEx GrowthYoY
22.61 %-24.58%
29.98 %-154.77%
-54.73 %-115.16%
361.09 %+15.89%
311.58 %+543.55%
48.42 %+278.62%
12.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Year-over-Year CapEx Growth of Acrobiosystems Co is 22.61 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year CapEx Growth Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

CapEx growth measures the percentage change in capital expenditures. Increasing CapEx can signal investment in future growth capacity.

To evaluate Year-over-Year CapEx Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year CapEx Growth.

Year-over-Year CapEx Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year CapEx Growth's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co